Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.56p 0.52p 0.60p - - - 0 06:39:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 0.2 -0.4 -0.0 - 10.20

Provexis (PXS) Latest News

More Provexis News
Provexis Takeover Rumours

Provexis (PXS) Share Charts

1 Year Provexis Chart

1 Year Provexis Chart

1 Month Provexis Chart

1 Month Provexis Chart

Intraday Provexis Chart

Intraday Provexis Chart

Provexis (PXS) Discussions and Chat

Provexis (PXS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-11-22 11:40:140.537,94041.92O
2017-11-22 10:49:080.5333,000174.24O
2017-11-22 09:49:040.5360,763320.83O
2017-11-22 09:06:020.5331,156164.50O
2017-11-22 08:57:310.539,80351.76O
View all Provexis trades in real-time

Provexis (PXS) Top Chat Posts

DateSubject
22/11/2017
08:20
Provexis Daily Update: Provexis Plc is listed in the Food Producers sector of the London Stock Exchange with ticker PXS. The last closing price for Provexis was 0.56p.
Provexis Plc has a 4 week average price of 0.42p and a 12 week average price of 0.40p.
The 1 year high share price is 1.25p while the 1 year low share price is currently 0.40p.
There are currently 1,820,818,174 shares in issue and the average daily traded volume is 2,362,021 shares. The market capitalisation of Provexis Plc is £10,196,581.77.
12/11/2017
02:18
wheelds: Closer To China:- On t.v program tonight a news program called "Closer to China" they talked about the latest 25.3 billion dollar trade deal between China and America, the highest ever, and stated this is just the beginning and non Chinese companies can now, in a joint venture, can partner in 51% of the joint venture. Now we all know DSM/Provexis is in a collaboration deal with the Chinese company By-Health to produce and sell new Fruitflow products, and that could now become a Joint Venture, and in China due to lower labor costs, profit margins will be higher, and in a joint venture By-Health and DSM and Provexis can come together and make one hell of a giant global and profitable company selling in China and around the world. . And its no co-incidence, in my opinion, Provexis share price has just risen as the possible knock on effects of this Closer to China agreement and possible Joint Venture between DSM and Provexis and By-Health and 51% shared partnership is realized.
10/11/2017
17:07
wheelds: Its worth pointing out that the share price keeps rising and on some sites the bid price is stated as 0.7p. I am looking forward to see what the share price and bid price starts up on Monday. But because we only have good news to come, in my opinion, the share price should now keep rising relative to potential and actual increased revenues.IMHO
09/11/2017
17:43
wheelds: ShArE PrICe UP 10% OR oNE TenTh today, and bid price up to 0.5p; so the ups and downs and the caps and locks with our share price is now free to go.IMHO All looking good as we move towards December results and getting news from China, and news of further increases in revenue. And today further good news of improved relationship growing between China and America which can only be a good thing for Provexis and our partner DSM once By-Health, in colaboration with Provexis starts producing Fruitflow products in China.IMHO
20/10/2017
00:11
wheelds: China congress meeting this week all about global trade expansion plans and ways and means to enable the prosperity of all of their 1.31 billion people. By-Health is a Chinese £3 billion pound company and is working in partnership with DSM and Provexis to further progress the benefits of our Fruitflow. Therefore in my opinion, By-Health is our saviour and if all works out new Fruitflow health products will be soon on sale in China and because, (which the west does not like) products produced in China relative to lower labour costs will results in new Fruitflow products exported around the world, (with DSM's assistance) and will be good value for money and attract more customers and Provexis will move into making a profit and then relative to DSM' s policy they will probably buy us out and in competition with By-Health who will also put a bid in, the share price will reflect this factor.. IMHO And then we can all retire.
26/7/2017
17:12
wheelds: HTTP://www.nutraingredients-asia.com/Regulation-Policy/Watch-Sports-nutrition-ready-to-rocket-in-China-as-e-commerce-sales-continue-to-set-the-pace Which reflects this statement:- "The Company expects to report revenues for the year ended 31 March 2017 of £228k, a 148% year on year increase (2016: £92k)." · The Company and DSM have seen an encouraging increase in brand awareness and customer interest in "Fruitflow® in recent months, with the total projected annual sales value of the prospective sales pipeline for Fruitflow standing at an all-time high level;" Lets hope this "Alltime high Level" results in a year on year increase in the value of the company and increase in share price; However, I still believe once we start making a profit DSM will buy us out.IMHO 3rd July 2017 HTTP://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PXS/13280648.html
20/7/2017
12:25
wheelds: £228k expected this year "148% year on year increase (2016: £92k)." Therefore:- if next year we only get a 100% increase on our £228k we will have 456k ending March 2018, and if it stays around 148% increase we will have £558k and be in profit this time next year. And share price should reflect this factor. And with the China deal and Japan deal year on year increase looks promising.IMHO
15/7/2017
12:57
wheelds: Lets hope the All time High statement results in an All time high share price by this time next year. "The Company expects to report revenues for the year ended 31 March 2017 of £228k, a 148% year on year increase (2016: £92k)." · The Company and DSM have seen an encouraging increase in brand awareness and customer interest in "Fruitflow® in recent months, with the total projected annual sales value of the prospective sales pipeline for Fruitflow standing at an all-time high level;" 3rd July 2017 HTTP://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/PXS/13280648.html
19/5/2017
17:16
wheelds: UP 12% TODAY; and normally share price does not go up on Fridays without good news, So ALL LOOKING GOOD. imho The only recent news out was we had just raised more money.
21/12/2016
01:34
wheelds: Looks like the next RNS will bring a share price rise:- (8 out of 10 Up) 07:00 20-Dec-2016 PXS Fruitflow and Blood Pressure - second stage update RNS +18.62% Up 07:00 23-Nov-2016 PXSStudy publication - comparison with aspirin RNS +87.90% Up 09:46 18-Nov-2016 PXS New Collaboration for Fruitflow RNS +50.00% Up 15:33 30-Sep-2016 PXS Result of AGM RNS +5.85% Up 17:08 15-Sep-2016 PXS Director/PDMR Shareholding RNS -1.46% Down 07:00 07-Sep-2016 PXS Preliminary Results RNS -6.49% Down 10:23 02-Sep-2016 PXS Holding(s) in Company RNS +9.27% Up 07:00 02-Aug-2016 PXS Results of Placing RNS +2.44% Up 07:00 12-Jul-2016 PXS Study Publication RNS +5.39% Up 07:05 29-Jun-2016 PXS Funding Update RNS +8.61% Up 07:00 29-Jun-2016 PXS Product Launch RNS +8.61% Up -------------------------------------------------------------------------------------------------------------------------------------------------------
23/11/2016
16:31
wheelds: News out today on Aspirin verus Fruitflow tests:- That's on top of the China Collaboration deal; so all looking good and being reported in the press. So all good for share price rise: And you never know, last time on news of Collaboration between Coca Cola on top of good news like this, shares price rose to 15p/20p before Coca Cola pulled out and share price fell; But this time I can't see the Chinese pulling out and the medical profession ignoring the aspirin - Fruitflow results this time around. "The study findings are significant and serve to demonstrate the potential effectiveness of Fruitflow® as a dietary supplement with a significant effect on blood flow, suitable for daily use in primary prevention of CVD, and with no adverse side effects." "The World Health Organization reports that more people die annually from CVDs than from any other cause¹ and the global market for cardiovascular disease, to include dietary supplements, is estimated to be in excess of $10 billion per year." "The US FDA states that after carefully examining scientific data from major studies, it has concluded 'the data do not support the use of aspirin as a preventive medication by people who have not had a heart attack, stroke or cardiovascular problems, a use that is called 'primary prevention.' In such people, the benefit has not been established but risks - such as dangerous bleeding into the brain or stomach - are still present.' ²
Provexis share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20171123 07:43:54